Post by Genentech

The FDA accepted our supplemental Biologics License Application for our medicine to treat systemic lupus erythematosus (SLE). SLE, the most common form of #lupus, is a potentially life-threatening autoimmune disease affecting more than 3 million people worldwide. There’s a critical need for a treatment option that can help reduce the daily impact of the disease on patients and has the potential to reduce steroid use. If approved, our medicine has the potential to offer an option to manage this disease. Learn more: http://spr.ly/6049BBBrYT

Video Content